These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26247532)

  • 1. Morphological and immunohistochemical profile of pancreatic neuroendocrine neoplasms.
    Simtniece Z; Vanags A; Strumfa I; Sperga M; Vasko E; Prieditis P; Trapencieris P; Gardovskis J
    Pol J Pathol; 2015 Jun; 66(2):176-94. PubMed ID: 26247532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
    McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
    Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of morphological features in lymph node metastasis between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinomas.
    Takahashi D; Kojima M; Morisue R; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Ikeda M; Ochiai A
    Pancreatology; 2020 Jul; 20(5):936-943. PubMed ID: 32553561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection.
    Milione M; Maisonneuve P; Pellegrinelli A; Spaggiari P; Centonze G; Coppa J; Delconte G; Droz Dit Busset M; Lanhazo O; Pruneri G; Mazzaferro V
    Eur J Surg Oncol; 2019 May; 45(5):755-760. PubMed ID: 30366875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors.
    Han X; Zhao J; Ji Y; Xu X; Lou W
    Tumour Biol; 2013 Oct; 34(5):2881-9. PubMed ID: 23686805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses.
    Sakai Y; Hong SM; An S; Kim JY; Corbeil D; Karbanová J; Otani K; Fujikura K; Song KB; Kim SC; Akita M; Nanno Y; Toyama H; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
    Hum Pathol; 2017 Mar; 61():148-157. PubMed ID: 27864124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center.
    Han X; Xu X; Jin D; Wang D; Ji Y; Lou W
    Pancreas; 2014 May; 43(4):526-31. PubMed ID: 24658317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Influence of Tumor Stage on the Prognostic Value of Ki-67 Index and Mitotic Count in Small Intestinal Neuroendocrine Tumors.
    Sun Y; Lohse C; Smyrk T; Hobday T; Kroneman T; Zhang L
    Am J Surg Pathol; 2018 Feb; 42(2):247-255. PubMed ID: 29016403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study.
    Zerbi A; Capitanio V; Boninsegna L; Delle Fave G; Pasquali C; Rindi G; Campana D; Falconi M;
    HPB (Oxford); 2013 Dec; 15(12):935-43. PubMed ID: 23472667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.
    Sugimoto M; Takagi T; Hikichi T; Suzuki R; Watanabe K; Nakamura J; Kikuchi H; Konno N; Waragai Y; Asama H; Takasumi M; Watanabe H; Obara K; Ohira H
    World J Gastroenterol; 2015 Jul; 21(26):8118-24. PubMed ID: 26185384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
    Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
    Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The associations between serum high-density lipoprotein cholesterol levels and malignant behavior in pancreatic neuroendocrine neoplasms.
    Quan L; Liu Y; Cui W; Wang X; Zhang W; Wang Z; Guo C; Lu C; Hu F; Chen X
    Lipids Health Dis; 2022 Jul; 21(1):58. PubMed ID: 35842659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.
    Primavesi F; Klieser E; Cardini B; Marsoner K; Fröschl U; Thalhammer S; Fischer I; Hauer A; Urbas R; Kiesslich T; Neureiter D; Zitt M; Klug R; Wundsam H; Sellner F; Karner J; Függer R; Cakar-Beck F; Kornprat P; Öfner D; Stättner S;
    Eur J Surg Oncol; 2019 Feb; 45(2):198-206. PubMed ID: 30262324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High vimentin expression with E-cadherin expression loss predicts a poor prognosis after resection of grade 1 and 2 pancreatic neuroendocrine tumors.
    Zhou B; Xiang J; Jin M; Zheng X; Li G; Yan S
    BMC Cancer; 2021 Mar; 21(1):334. PubMed ID: 33789624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
    Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
    World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
    Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropilin-1 (NRP-1) upregulated by IL-6/STAT3 signaling contributes to invasion in pancreatic neuroendocrine neoplasms.
    Yang Y; Yang L; Li Y
    Hum Pathol; 2018 Nov; 81():192-200. PubMed ID: 30420046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.